Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
11/10/201710:27AMGLOBEInovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets cancers... More...>>
11/09/20178:00AMGLOBEInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare ConferencePresentation and 1x1 meetingsDr. Niranjan Y. Sardesai, COO11:45 AM ET, November 15, 2017New... More...>>
11/08/20174:05PMGLOBEInovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million for the same period in 2016. Total operating... More...>>
11/01/20179:18AMGLOBEInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhi...
PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today initiated a phase 1b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) designed to evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc... More...>>
10/26/20178:00AMGLOBEInovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
PLYMOUTH MEETING, Pa., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 third quarter financial results on Wednesday, November 8, 2017 at 4:30 p.m. ET. A live and archived version of the audio presentation... More...>>
10/24/20178:00AMGLOBEInovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study...
PLYMOUTH MEETING, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus. Lassa is a virulent hemorrhagic virus, similar to Ebola, which... More...>>
10/16/20177:00AMGLOBEInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inh...
PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens... More...>>
10/05/20177:00AMGLOBEInovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
PLYMOUTH MEETING, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO)  reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus. The phase 1 trial of Inovio’s DNA-based Zika vaccine (GLS-5700) induced... More...>>
09/21/20178:00AMGLOBEInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Prec...
PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from... More...>>
09/18/20178:00AMGLOBEInovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
PLYMOUTH MEETING, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Korean Ministry of Food and Drug Safety approved the initiation of a study to evaluate GLS-5300, Inovio’s vaccine against the MERS virus (Middle East Respiratory Syndrome), in a phase 1/2a trial... More...>>
09/11/20178:00AMGLOBEInovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with R...
PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent... More...>>
08/23/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Citi’s 12th Annual Biotech ConferencePanel Discussion: I/O Beyond PD-1: Opportunities & ChallengesDr. J. Joseph Kim... More...>>
08/08/20174:14PMGLOBEInovio Pharmaceuticals Reports 2017 Second Quarter Financial Results
PLYMOUTH MEETING, Pa., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended June 30, 2017. Total revenue was $20.4 million for the three months ended June 30, 2017, compared to $6.2 million for the same period in 2016. Total operating expenses... More...>>
07/26/20178:00AMGLOBEInovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
PLYMOUTH MEETING, Pa., July 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 second quarter financial results on Tuesday, August 8, 2017 at 4:30 p.m. ET. A live and archived version of the audio presentation will... More...>>
07/19/201710:10PMGLOBEInovio Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share.  The gross proceeds to Inovio from the offering are expected to... More...>>
07/18/20174:01PMGLOBEInovio Announces Proposed Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Inovio expects to grant the underwriters an option to purchase up to an additional $11.25... More...>>
07/06/20178:00AMGLOBEInovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with multiple viruses from both influenza A and B types... More...>>
06/28/20178:00AMGLOBEInovio Announces Leadership Appointments
PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson... More...>>
06/19/20178:00AMGLOBEInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging Infectious Diseases,” at the 2017 BIO International Conference... More...>>
06/15/20178:00AMGLOBEInovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Ef...
PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this vaccine with GeneOne Life Science, Inc. (KSE:011000) and academic... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20171119 17:45:28